Member Info for Dosanddonts

Point is hopefully we are seeing the end & the share value we all deserve LTH!

This share has been a real learning curve for me regarding selling at the peaks & buying at the lows! Have done neither just held on as I see more value long term but also so difficult! But hopefully my holding will pay off, but my god how I wish I had sold & bought at the right times would had made a fortune & guess many others would agree! Don’t kick yourself like me as if it was that easy everyone would be at it & making a fortune.

Share price increase is Not viagra affecting eye sight when it kills people & still people continue to use it. Was hoping for a late RNS but who can tell! Everyone is sitting on tender hooks & we will probably see this for months to come until news hits which we are all expecting.

Lombard have a massive stake in a very small AIM company! They will never get rid of their large stake in a short time frame! Which means to me they are expecting a sustained large increase or a buy out! They would have reduced their holding otherwise

Obviously very excited if buys FUM generally release news on a Friday so here’s hoping for a positive RNS 2mor!

Sorry & a second one at £123K WoW

Anyone know if this was a sell or buy?

I am a LTH of this share & it’s been & still is like a rollercoaster! This additional 6month US confirmatory trial to me is what’s holding the big deals back as you never know with FUM so let’s all keep our fingers crossed! I would love to say it’s a done deal but as all investors know there’s no such thing especially with FUM!

As expected not much movement! We will only see significant movement when the uk/eu & US deals Come through. We know it & the BOD know it, so what is going on???? I hope they haven’t spent the last 12month securing this one deal, so let’s see the rest! Maybe this is the start of drip feeding the deals through one by one, let hope!

Jet7-I agree we have been on a go slow since uk/eu certification & they seem to be in no hurry. They have suspended all work on other products to concentrate on Eroxon since last Dec to get to market! This cannot be good long term for FUM to have all there eggs in one basket unless there plan is to sell the company but then again several potential products should be worth more than one!So let’s hope they have a plan we just don’t know what it is! On a positive note, the large institutional investors are still in with large holdings that some have increased recently! That’s interestingly to me & is news in itself.

In the last RNS I think! it said they were putting on hold all other development work to concentrate on Eroxon! If that’s the case what is going on? there must be further NEWS or have they been sitting on their arses! I appreciate this is a wise move to conserve funds but seems short sightedness to me considering how long its taking. If they can’t get this big boy over the line which to be honest they seem to be struggling with again then they will have real problems! This is the problem with FUM too small & limited funds means they miss the boat in my opinion!

They have a product, they are just F in useless!

Maybe we are pulling distribution in Russia as we don’t need anymore little Putins running about & that’s the reason for the SP drop hahaha!

This is not the first time we have been left in limbo by the BOD, anyone here for some time will remember the condom years recently in fact! Got marketing approval made some S H I T T Y deals before going it alone all because they couldn’t dot the i’s & cross the T’s! Issues with shelf life & even when that was fixed still failed to get it up! Disappointing really they have dropped everything to focus on Eroxon so what is happening BOD’s where is the movement? May as well have sought approval in the US first as we have now been sitting on approval for EU/UK for nearly a year WTF!

News is due soon! So hopefully the share price is creeping up in anticipation of one or all of the following!
1-Eu/UK deal
2-Update on additional trial being conducted in the US, which is not a clinical trial to prove Eroxon works but to provide 6month data versus 3months already provided. More a formality!
3-Patent extensions for Eroxon formulation
4-US deal which I guess won’t come until the 6month trial is completed or maybe on US approval.
5-Eroxon sale into all markets 2022
I would have expected the BOD to be updating the market on a regular basis, it’s now been 3month since the last update do lets see!

I topped up when the institutional investor increased its stake by £1million or 1% to £26million or 26% approximately! Bit of a gamble but why would a long standing investor top up at this stage in the game unless they know something we don’t! I feel it’s just a waiting game now but am also really annoyed with the BOD for lack of info but time will tell.

More news yet to come even before sales, so it all looks good! If eu/uk deals come 50% upside! If US approval comes 50% upside! Can’t really fail! Proof will be sales but we will see rises before then!

I agree where are the BOD? What are they doing? Surely they must have a clear route to market by now & how they are going to achieve it? If I hear they are in advanced discussions again! Seriously that is not information, they have been spinning that one for years!

Makes no sense Lombard have bought £1millon & some decent buys today but SP has fallen??

Friday 21st Jan 2022
Liberum Capital sees close to 80% upside to the current price for Ilika PLC (AIM:IKA, OTCQX:ILIKF) as the company advances its solid-state battery products.

The stockbroker’s ‘buy’ recommendation comes with a 245p price target (current price: 138p).

Ilika’s solid-state batteries are a key enabler for companies seeking to develop a variety of smarter, smaller and more responsive implantable medical devices, analyst Adam Collins said in a note.

Collins highlighted: “Ilika has seen enquiries from 16 medical device developers and will have manufacturing capacity for c300,000 devices per annum before licensing.

“The potential is significant given there are 2 million knee/hip implants per annum and c30mln fatalities from chronic heart disease.”

Ilika has few competitors, the analyst noted, with three competitors in the micro battery sector which Collins says have a different focus whereas existing medical battery makers are yet to develop solid-state capabilities.